Hansoh Pharmaceutical has given a bullish assessment of China’s innovative pharma sector, arguing that the industry is “fully transitioning from the ‘follower’ to the ‘frontrunner’ phase.”
Hansoh Pharmaceutical has given a bullish assessment of China’s innovative pharma sector, arguing that the industry is “fully transitioning from the ‘follower’ to the ‘frontrunner’ phase.”